Clinical Pipeline
- Clinical Pipeline
- Preclinical Pipeline
- Diagnostic Program
AC Immune develops innovative therapeutics with “best in class” potential against Alzheimer's Disease along three axes: vaccines, antibodies and small molecules. In every axis one product is currently in clinical development. These product programs are based on the Abeta hypothesis, which assigns a central role to abnormal processing of amyloid precursor protein (APP), yielding a fragment called Abeta. Abeta production and aggregation are seen as one key event in nerve cell disruption and destruction.
ACI-24 (Active Alzheimer's Disease Immunotherapy)
ACI-24 has been developed from the SupraAntigen™ Platform and is designed to act as an active vaccine stimulating the patient's immune system to produce beta-sheet conformation-specific antibodies that prevent plaque deposition or enhance clearance of plaques. During preclinical development, the ACI-24 has shown high efficacy in vivo by memory restoration and plaque reduction. The vaccine is also characterized by a very high specificity due to generating a conformation-specific antibody response. The favorable safety profile of ACI-24 is underlined through the absence of local inflammation in relevant models as well as its T-cell independent mechanism shown in preclinical development. This product entered a combined Phase I/IIa clinical trial in 2009 which is currently ongoing.
Crenezumab (Passive Alzheimer's Disease Immunotherapy)
The anti-Abeta antibody crenezumab is being developed by Genentech, Inc. - under an exclusive licensing agreement with AC Immune - for an Alzheimer´s Disease immunotherapy against Abeta. This monoclonal antibody has as well been developed from the SupraAntigen™ Platform. The pre-clinical assessment of the antibody has shown high specificity and efficacy as well as a favorable safety profile. Genentech was granted Investigational New Drug clearance in 2008 by the FDA and fast track status was designated. The Phase I clinical study has been completed in 2010 and Phase II started in of 2011. (further information on the trial). A landmark Alzheimer´s prevention trial with the antibody has been announced in 2012.
